Darzalex 1800 mg solution for subcutaneous injection — original (Janssen) Darzalex is prescribed: in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma. +380996042415

Darzalex® is indicated:

 in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplantation;

 as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received prior therapy including a proteasome inhibitor and an immunomodulatory agent and who have had disease progression during their most recent therapy;

 as part of combination therapy with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy.